Biotech RadarJobs updated

COMPANY

Triveni Bio

HQ: Watertown, MA source · triveni.bio ↗

Clinical Phase 2

Location: Watertown, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Keywords: Atopic Dermatitis TRIV-573 TRIV-509

$65.0MRaised (2 yrs)2Trials (company is sponsor)

Raises and deals from press releases

Raises announced in these releases: $180M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

  1. Raise Private equity round — Series C: $65M (total, as published), announced Jun 17, 2026. Source: company's own press page. source ↗
  2. Raise Series C · $65M source ↗
  3. Trial start Phase 2: A Study Evaluating TRIV-509 in Atopic Dermatitis source ↗
  4. Raise Series B · $115M source ↗
  5. Trial start Phase 2: A Study Evaluating TRIV-573 in Atopic Dermatitis source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $65.0M. Last 2 years.

Clinical trials (lead sponsor) 2

RecordTitlePhaseStatusStartPrimary completion
NCT07782333A Study Evaluating TRIV-573 in Atopic DermatitisPhase 2Not yet recruiting2026-082027-08 (estimated)
NCT07167758A Study Evaluating TRIV-509 in Atopic DermatitisPhase 2Active, not recruitingAug 26, 20252026-10 (estimated)

Raises and investors new

Form D raises come from the company’s own SEC filing (last 2 years).

Feedback